Skip to content
← Catalog

Capstan Therapeutics · in vivo CAR-T via LNP/mRNA (acquired by AbbVie)

Capstan Therapeutics · in vivo CAR-T 公司 · LNP/mRNA delivery 平台 · 2025 被 AbbVie 以 $2.1B 收购(per OPORD-002 verify priority list)。 AbbVie 此次收购是大药企第二轮进入 in vivo CAR-T 空间的明确信号。 对 SunVax 的对标维度:LNP 同 modality · therapeutic asset 不同 business model。

Type
company
Domain
conference
Grade
conference
License
LIGHT_HOPE_proprietary
evidence_grade
B
category
in_vivo_car_t_lnp_mrna
status
draft
instance_tag
sunvax-antibody-2025
platform_tech
LNP / mRNA · in vivo CAR-T delivery
acquisitions
[object Object]

Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.